Back to Journals » Pediatric Health, Medicine and Therapeutics » Volume 8

Current perspectives on the optimal management of infantile hemangioma

Authors Grzesik P, Wu JK

Received 6 May 2017

Accepted for publication 6 September 2017

Published 6 December 2017 Volume 2017:8 Pages 107—116

DOI https://doi.org/10.2147/PHMT.S115528

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Dr Roosy Aulakh


Peter Grzesik, June K Wu

Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY, USA

Abstract: Infantile hemangiomas (IHs) are the most common benign tumor of infancy. As our understanding of their pathobiology has evolved, treatment has become more focused and tailored to specifically treat IH while minimizing adverse effects. Propranolol has gained FDA approval as the first medical therapy for a traditionally surgical disease. This review provides readers with an overview of IH, treatment modalities, and addresses specific considerations in IH disease management.

Keywords: infantile hemangioma, medical treatment indications, propranolol, complications of infantile hemangioma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]